Cargando…

Prostate cancer survivors: Risk and mortality in second primary cancers

To assess etiological and clinical consequences of second primary cancers (SPCs) in prostate cancer (PC) patients, we followed newly diagnosed patients to identify men who were diagnosed with a SPC and recorded their causes of death. We used the Swedish Family‐Cancer Database to assess relative risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Chattopadhyay, Subhayan, Zheng, Guoqiao, Hemminki, Otto, Försti, Asta, Sundquist, Kristina, Hemminki, Kari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246949/
https://www.ncbi.nlm.nih.gov/pubmed/30277023
http://dx.doi.org/10.1002/cam4.1764
_version_ 1783372409100828672
author Chattopadhyay, Subhayan
Zheng, Guoqiao
Hemminki, Otto
Försti, Asta
Sundquist, Kristina
Hemminki, Kari
author_facet Chattopadhyay, Subhayan
Zheng, Guoqiao
Hemminki, Otto
Försti, Asta
Sundquist, Kristina
Hemminki, Kari
author_sort Chattopadhyay, Subhayan
collection PubMed
description To assess etiological and clinical consequences of second primary cancers (SPCs) in prostate cancer (PC) patients, we followed newly diagnosed patients to identify men who were diagnosed with a SPC and recorded their causes of death. We used the Swedish Family‐Cancer Database to assess relative risks (RRs) and causes of death in SPCs until the year 2015 in patients with a PC diagnosis between 2001 and 2010. Among a total of 4.26 million men, 76 614 were diagnosed with PC at the median age of 71 years. Among them, 8659 (11.3%) received a subsequent diagnosis of SPC after a median follow‐up of 4 years. The most common SPCs were colorectal, skin, bladder, and lung cancers, melanoma, and non‐Hodgkin lymphoma. The ranking was almost identical with first cancers among elderly men in Sweden. The RR for SPCs in prostate‐specific antigen—detected PC was approximately equal to RR in other PC. Mortality patterns of PC patients were distinct depending on the presence or absence of SPC. Among patients with SPC, 47.8% died as a result of the corresponding SPC, followed by other causes (22.2%) and PC (18.1%). For patients without SPC, PC and non‐neoplastic causes almost matched each other as the main causes of death (48.5% and 47.8%). The results suggest that SPCs appear autonomous from primary PC and reflect incidence and mortality of first cancers in general. SPC was the most common cause of death in patients with SPC; close to half of the patients died due to SPC. For improved survival in PC patients, prevention and early detection of SPCs would be important, and the present results suggest that risk factors for SPC in PC are the same as those for first cancer in general.
format Online
Article
Text
id pubmed-6246949
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62469492018-11-26 Prostate cancer survivors: Risk and mortality in second primary cancers Chattopadhyay, Subhayan Zheng, Guoqiao Hemminki, Otto Försti, Asta Sundquist, Kristina Hemminki, Kari Cancer Med Cancer Prevention To assess etiological and clinical consequences of second primary cancers (SPCs) in prostate cancer (PC) patients, we followed newly diagnosed patients to identify men who were diagnosed with a SPC and recorded their causes of death. We used the Swedish Family‐Cancer Database to assess relative risks (RRs) and causes of death in SPCs until the year 2015 in patients with a PC diagnosis between 2001 and 2010. Among a total of 4.26 million men, 76 614 were diagnosed with PC at the median age of 71 years. Among them, 8659 (11.3%) received a subsequent diagnosis of SPC after a median follow‐up of 4 years. The most common SPCs were colorectal, skin, bladder, and lung cancers, melanoma, and non‐Hodgkin lymphoma. The ranking was almost identical with first cancers among elderly men in Sweden. The RR for SPCs in prostate‐specific antigen—detected PC was approximately equal to RR in other PC. Mortality patterns of PC patients were distinct depending on the presence or absence of SPC. Among patients with SPC, 47.8% died as a result of the corresponding SPC, followed by other causes (22.2%) and PC (18.1%). For patients without SPC, PC and non‐neoplastic causes almost matched each other as the main causes of death (48.5% and 47.8%). The results suggest that SPCs appear autonomous from primary PC and reflect incidence and mortality of first cancers in general. SPC was the most common cause of death in patients with SPC; close to half of the patients died due to SPC. For improved survival in PC patients, prevention and early detection of SPCs would be important, and the present results suggest that risk factors for SPC in PC are the same as those for first cancer in general. John Wiley and Sons Inc. 2018-10-01 /pmc/articles/PMC6246949/ /pubmed/30277023 http://dx.doi.org/10.1002/cam4.1764 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Chattopadhyay, Subhayan
Zheng, Guoqiao
Hemminki, Otto
Försti, Asta
Sundquist, Kristina
Hemminki, Kari
Prostate cancer survivors: Risk and mortality in second primary cancers
title Prostate cancer survivors: Risk and mortality in second primary cancers
title_full Prostate cancer survivors: Risk and mortality in second primary cancers
title_fullStr Prostate cancer survivors: Risk and mortality in second primary cancers
title_full_unstemmed Prostate cancer survivors: Risk and mortality in second primary cancers
title_short Prostate cancer survivors: Risk and mortality in second primary cancers
title_sort prostate cancer survivors: risk and mortality in second primary cancers
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246949/
https://www.ncbi.nlm.nih.gov/pubmed/30277023
http://dx.doi.org/10.1002/cam4.1764
work_keys_str_mv AT chattopadhyaysubhayan prostatecancersurvivorsriskandmortalityinsecondprimarycancers
AT zhengguoqiao prostatecancersurvivorsriskandmortalityinsecondprimarycancers
AT hemminkiotto prostatecancersurvivorsriskandmortalityinsecondprimarycancers
AT forstiasta prostatecancersurvivorsriskandmortalityinsecondprimarycancers
AT sundquistkristina prostatecancersurvivorsriskandmortalityinsecondprimarycancers
AT hemminkikari prostatecancersurvivorsriskandmortalityinsecondprimarycancers